Journal of Advances and Scholarly Researches in Allied Education
Vol. 19, Issue No. 4, July-2022, ISSN 2230-7540

A Study the adverse drug reactions use the Drug-Induced Hepatotoxicity and Hepatoprotectives

Santosh Kumar Chaturvedi[1]*, Dr. Mukesh Kumar Gupta[2]

[1] Research Scholar, Lords University, Alwar, Rajasthan

[2] Research Supervisor, Lords University, Alwar, Rajasthan

Abstract - Adverse drug reactions are frequent & significant source of health issues. Liver toxicity is the frequent causes of pharmacovigilance safety complaints and the removal of an approved medication from the market over the past ten years. The liver is a key organ in the systemic detoxification & deposition of chemicals, both endogenous & foreign. The pharmaceutical industry & drug regulatory organisations are also challenged by liver dysfunction in addition to healthcare professionals. Drug-induced hepatotoxicity, commonly known as drug-induced liver injury (DILI), is a significant clinical issue that has overtaken other causes of acute liver failure & transplantation in Western nations. One of the main causes of both acute & chronic liver damage is drug-induced hepatotoxicity. Using keywords like ADR, Drug-Induced Hepatotoxicity, Hepatoprotectives, Liver Injury, Methionine, & N-Acetyl -L-Cysteine, a thorough review explore was conducted for the current review study.

Keywords - Drug-Induced Liver Injury, Hepatotoxicity, Hepatoprotectives, Liver Injury

----------X----------

INTRODUCTION

Adverse drug reactions (ADRs) are frequent and a significant source of health issues. Since the liver is a key organ in the body's detoxifying processes and the accumulation of both endogenous and external chemicals, liver diseases are critical health issues that continue to have a significant impact on morbidity & death rates throughout a wide clinical histological spectrum. The parent drug administered is frequently responsible for producing the desired therapeutic effect; however, adverse events or toxic effects produced by the drugs are not just related to the parent compound where the drug's metabolites produced by the enzymes, light, or reactive oxygen species (ROS) contribute to the damages done, as demonstrated by the hazardous reactive intermediate, a strong oxidizing metabolite of acetaminophen that interacts to nucleophiles like (Dass Ervilla 2018) Given these facts and the significance of medication-induced liver damage, For the function of this review study, a comprehensive research search was undertaken using the terms ADR, drug-induced hepatotoxicity, hepatoprotectives, hepatotoxicity, & liver injury. Both methionine & N-acetyl-L-cysteine.

When exposed to medications, chemicals, & xenobiotics, the liver, a key organ involved in drug metabolism, is vulnerable to harm, which is typically indicated by the liver's raised serum enzyme levels.

The term "hepatotoxins" refers to substances that harm the liver. Both idiosyncratic and nonidiosyncratic hepatotoxicity are possible. Hepatotoxic medications like antitubercular drugs (Isoniazid, Rifampicin, Pyrazinamide) and non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, diclofenac, sulindac, aspirin, & paracetamol, which are frequently utilised anti-inflammatory, analgesics, & antipyretic preparations, have raised serious concerns about drug-induced liver toxicity.

DRUG-INDUCED HEPATOTOXICITY: A GLANCE

It was discovered that the DILI was linked to a number of risk variables, including race, alcohol consumption, pre-existing liver illness, genetic factors, drug formulations, & number of host characteristics, including gender, age, nutritional status, body mass index, metabolic disorders, renal failure, hepatitis C, & acquired immunodeficiency syndrome (AIDS). [Fernando Bessone 2010] The Food & Drug Administration (FDA) has pulled two medications off the market in the last five years due to severe liver injury, a possible risk that was not completely appreciated during the preapproval clinical trials. Any reports of negative medication reactions cause the public to dread and doubt the

www.ignited.in

actions of the FDA & pharmaceutical sector. [William M. 2003]

According to reports, medication-induced hepatic damage accounts for more than 50% of cases of acute liver failure in the U.S & currently one of the most often cited reasons for pulling an approved drug off the market. According to some estimates, more than 75% of unusual drug responses result in liver transplantation or death. Critical analysis of these instances has revealed that there were occasionally clues in the nonclinical data available at the time of marketing application that, looking back, could have foreseen hepatotoxicity. Drug-induced hepatotoxic responses can have many different forms and sources, and their onset times can range from being very brief to having a protracted latency. [Khouryx T, 2015] Clinically, liver necrosis, hepatitis, cholestasis, vascular abnormalities, & steatosis are the most important effects. It is significant to emphasise that when interpreting results & determining their applicability to people, species differences in drug & target drug metabolism must be taken into account. Steatosis, for instance, has important clinical ramifications such as Non-Alcoholic Steato-Hepatitis (NASH), although it is typically a less relevant finding non-clinically, especially if found in rats.

RUGS CAUSING HEPATOTOXICITY: INCIDENCE & PREVALENCE

Most recently, troglitazone and bromfenac have been used as examples of hepatotoxic adverse medication events that have led to the failure of several promising medicines. The range of liver toxicity brought on by NSAIDs is constantly growing, , includes reports of toxicity in minors, interaction toxicity in hepatitis C patients, and acknowledgement of the toxicity of both preferential and selective cyclooxygenase-2 inhibitors [Zimmerman 1981]. Angiotensin Receptor & Converting Enzyme Inhibitors are increasingly linked to cases of liver damage [Chitturi S 2002]. Acarbose, Gliclazide, Metformin, & Human Insulin have all been linked to anti-diabetic medications harming the liver. Even if there have been a few reports of severe hepatitis, the more recent Thiazolidinediones don't seem to have Troglitazone's hepatotoxic potential. Although "statins" have been related to liver damage, this toxicity is less common than in the general population, and the utility of biochemical monitoring has not been established. Recent developments in the field of anticonvulsant hepatotoxicity include the identification of the reactive metabolite syndrome, the identification of the danger signs of valproic acid toxicity, the potential protective effects of carnitine, & toxicity of second-line antiepileptic medications. Selective serotonin reuptake inhibitors, in particular, have been related to liver damage while using newer psychiatric medications (SSRIs). There is proof that hepatotoxic medicines such acetaminophen, tamoxifen, diclofenac, & troglitazone can produce reactive metabolites, which have been linked to reports of liver damage. Also important in the aetiology of liver disease may be oxidative stress & low glutathione levels. Even after accounting for increased medicine use, the incidence of major adverse drug responses rises with age. (2007) DILI and the majority of adverse drug responses (ADRs) in older individuals are dose-related [Routledge et al. 2004]. Hepatotoxicity or cardiac toxicity is currently the main factor causing drug development to stop in phase IIII or to be withdrawn from the market. Drug-induced hepatotoxicity is the main reason why the FDA in the US denies drug approval and requires drug discontinuation. More than a thousand medications and substances have been linked to liver damage (Porceddu et al., 2012). Injuries to the liver caused by drugs may be the cause of 10% of acute hepatitis cases, 5% of hospital admissions, and 50% of acute liver failures (Pandit 2012). The fact that liver transplantation or mortality occurs in more than 75% of idiosyncratic medication reaction instances is extraordinary (Ostapowicz et al., 2002). Acute liver illness is frequently brought on by drug-induced liver injury, which has a 10-percent fatality rate (Bjornsson et al., 2013).

HEPATOPROTECTIVE AGENTS

Due to their active roles in the supplementary therapy of liver disease, hepatoprotective drugs have received attention (Flatland, 2003; Sartor 2003; Twedt, 2004). A substance must be safe, nontoxic, and efficient for its intended application in order to be used as a drug. Only after completing the lengthy and expensive FDA drug approval process can the medication be made available on the market. In addition to contemporary medications, there are a number of hepatoprotective substances, including milk thistle (Silymarin), vitamin C, L-carnitine, and N-acetylcysteine. The literature on medical plants with hepatoprotective properties, various hepatotoxins were employed by various researchers to assess the activity in vitro & in vivo models. In several investigations, the same plant was screened using multiple hepatotoxins. Carbon tetrachloride was the hepatotoxin that was most frequently utilised (CC14). Regardless of the administration method, CCl4 was employed in close to 80% of investigations. The total dose of CCI4 delivered ranged from 0.2-2 ml/kg for acute liver injury with a one-day treatment to 1.5–5 ml/kg in divided doses over the course of one week for chronic (reversible), and 12–20 ml/kg for 5–12 weeks (irreversible). The most frequently used metrics to appraise the hepatoprotective activity were morphological, such as liver weight & volume, biochemical estimates, such as measurement of transaminase activity, SGPT, SCOT, alkaline phosphatase, serum bilirubin, total serum proteins, albumin, globulin, & prothrombin time, functional metrics, such as pentobarbitone & hexobarbitone sleeping time, and eventually histopathological A rise in the percentage of cells, an acceleration of oxygen consumption, and a reversal of enzymatic values like SGPT, SCOT, and ALT in primary cultured hepatocytes were observed in some studies using invitro methods for screening remedial plants; these techniques have been most frequently used by

foreign researchers (especially Japanese investigators). They use primary grown hepatocytes in their standardised invitro screening techniques. This invitro approach of testing medicinal herbs for their hepatoprotective function is not much more widely employed in India, most likely because of technical issues and a lack of facilities for hepatocyte cultivation and maintenance. This approach makes it possible to do primary screening on a large scale, followed by more in-depth research. Since more animals (rats or mice) are needed for in vivo procedures, they take more time and money to complete, and only one plant may be tested at once due to the high expense of biochemical & histopathological examinations. (Das et al., 2011; Vargas-Mendoza et al., 2014)

LITERATURE REVIEW

Deepasree Sukumaran **et al. (2022)** First-line anti-TB (ATT) medications can have a major side effect known as DILI that restricts the ability to cure TB. One of the postulated reasons for ATT-induced DILI is oxidative stress, which is caused by tissue inflammation brought on by free radical burst and inadequate food intake in TB. N-acetylcysteine (NAC) strengthens the cellular antioxidant defence system, which protects the liver. There aren't many studies examining NAC's impact on ATT-induced DILI in the Indian community. This study has parallel groups & prospective, randomised, double-blind, & placebo-controlled. 38 newly diagnosed TB patients who were receiving first-line ATT and had normal LFTs were enrolled, and they were randomly assigned to receive either NAC 600 mg tablet or placebo twice daily for 4 weeks, followed up for another 4 weeks. At baseline, 2, 4, and 8 weeks, the LFT [AST, ALT, ALP, & Total bilirubin] was measured. At baseline, 4 and 8 weeks, oxidative-stress biomarkers (MDA, NO, & GSH) and quality of life (QOL) using the SF-36 questionnaire were measured. ADRs were kept track of at each visit. The pill-count method was used to evaluate compliance. Each group's initial features were similar to the other. At 4 weeks, ALT (p 0.01), ALP (p 0.01), and total bilirubin (p 0.001) were significantly lower in the NAC group than at baseline. In the NAC group, AST, MDA, and NO showed reductions of 19%, 21.60%, and 5.50% from baseline, respectively, while GSH showed an increase of 2.60% from baseline after 4 weeks, but these results were not statistically significant. Even at the end of 8 weeks, these effects in LFT & oxidative indicators were still present. Both groups' QOL significantly increased from the starting point (p 0.05). At 4 weeks, a between-groups study exposed a considerable decrease in ALT (p 0.05) & AST (p 0.05) in the NAC group, while bilirubin, MDA, NO, and GSH exhibited improvement relative to the placebo group at the same time although this improvement was not statistically significant. Even after 8 weeks had passed, the LFT & oxidative indicators were still improving. The most frequent ADRs, with similar incidence in both groups, were itching & rashes. In both groups, treatment compliance was high. It is possible that NAC has a hepatoprotective effect because of the significant improvement in liver function markers. This observed effect, which was discovered to be durable after 8 weeks, indicates that NAC has a sustained hepatoprotective impact. Further verification of NAC's hepatoprotective effect will require long-term research with large sample sizes.

Xianni WEI (2022) to research the causes, symptoms, & treatments of DILI at our hospital over the past few years and to provide information for the selection and administration of therapeutic drugs. Between January 1, 2013, and January 1, 2020, information on patients with DILI was gathered and examined. Anti-infective pharmaceuticals, traditional Chinese medicine, anti-lipidemic drugs, anti-tumor drugs, antipyretic & analgesic drugs were the main pharmacological classes that caused DILI. DILI was most likely to happen four weeks after taking medication (72 cases). Male patients had a slightly greater incidence of DILI (51.0%) than female patients (49.00%), and their average age was 51.017.7. Patients aged 41 to 60 had the highest incidence of DILI (38.00 percent). 82 cases involved problems because of pre-existing illnesses. Between special genders, age groups, or individuals with or without previous disorders, there was no discernible variation in the incidence of DILI (P>0.05). Following drug-induced liver damage, drug use was discontinued in 72 cases, continued in 23 cases, and reduced in 3 cases. 91 patients were treated with hepatoprotective medications; of those, 23 cases were cured, 45 cases improved 14 cases were not cured, and 9 cases remained unidentified. Anti-infective medications are the most common drugs to cause DILI, followed by Chinese medicine. The incidence of DILI is disproportionately high in middle-aged and elderly adults, and the prognosis is generally positive. Clinicians should step up monitoring and take early action to stop and lessen the occurrence of DILI.

Maryam Mirahmad et al. (2022) One of the main reasons why medicines are withdrawn after approval is DILI. As a consequence, there is a growing demand for precise predictive in vitro tests that consistently identify drug candidates that are hepatotoxic while decreasing the amount of time, money, and animal testing required for drug discovery. Research using in vitro hepatocytes has

enhanced our understanding of the underlying mechanisms of chemical toxicity & help us prioritise therapeutic options with low hepatotoxicity risk. Thus, throughout the past few decades, numerous in vitro systems have been created. This study intends to describe in-depth the creation and validation of two-dimensional (2D) & three-dimensional (3D) culture techniques on hepatotoxicity screening of substances and to emphasise the key variables influencing experiment predictive power. In order to achieve this, we first provide an overview of some of the known hepatotoxicity mechanisms and associated assays that are used to evaluate DILI mechanisms, after which we talk about the difficulties and limits of in vitro models.

Huihui Su **et al. (2022)** The liver, a vital internal organ & digestive gland, is crucial to metabolism and detoxification in the human body. The liver is vulnerable to damage as a consequence of regular exposure to hazardous substances. A kind of ROS/RNS called peroxynitrite (ONOO) is often created by the diffusion-limited interaction of O2 and NO. The production of ONOO was connected to the DILI, according to some evidence. To further understand the causes of drug-induced hepatotoxicity, precise analytical methodologies for identifying ONOO of DILI-related disorders must be developed. In this study, the probe BDPP was successfully created & used to detect peroxynitrite in zebrafish and living cells. It has a quick response time, excellent selectivity, and good senstivity. Additionally, the probe BDPP could identify the up-regulated expression of ONOO and assess the NAC remediation in the APAP-induced hepatotoxicity model cells. For such detection of ONOO during tests for drug-induced hepatotoxicity, the probe BDPP may be a helpful technique.

Manisha Parthasarathy and associates (2021) Clinical hepatic dysfunction is largely induced by synthetic medicines and other xenobiotics, which has been a serious challenge for both patients and doctors. Because of their extensive availability in nature, pharmacological advantages, & lack of side effects, traditional medicines are employed as alternatives to conventional therapies. Essential components of plants, phytochemicals lessen necrotic cell death, repair the antioxidant defence system, restrict oxidative stress, avoid tissue inflammation, and stop mitochondrial malfunction. The potential use of herbal plants or their phytochemicals in the treatment of drug-induced hepatotoxicity was the main focus of this review.

Jiao Chen and other (2021) Clinical medicine & drug discovery both continue to be concerned with DILI. The clinical techniques used now to measure DILI by looking at serum enzymes are still not ideal. According to recent studies, fluorescence sensors would be effective instruments for both diagnosing DILI and accurately detecting the concentration & distribution of DILI indicators in real-time, in situ, and with little damage to biosamples. This article focuses on the evaluation of DILI, provides an overview of the existing mechanisms underlying DILI, and lists the design approaches used to create fluorescence sensors for DILI indicators, such as ions, small compounds, & associated enzymes. The development of DILI diagnostic fluorescence sensors has some difficulties. We are confident that these design approaches and evaluation hurdles for DILI will motivate chemists and present them with chances to further create alternative fluorescence sensors for precise disease diagnosis and treatments.

Richard H. Norman (2020) ADRs are a frequent reason for drug discovery & development attrition, and DILI is the main reason for stopping the development of preclinical & clinical drugs. This viewpoint provides an overview of several of the recognised DILI processes and assessment techniques used to gauge and reduce DILI risk. The predictive value of each end point has been determined by literature reviews, retrospective studies using confirmed DILI-associated medicines from the Liver Tox Knowledge Base (LTKB), and combination techniques of various methods. Useful DILI predictability is provided by in vitro studies that evaluate mitotoxicity, RM production, hepatocyte cytolethality, BSEP, as well as physicochemical qualities or clinical dosage. This perspective also describes various methods medicinal chemists have employed to lower the risk of DILI when optimising medication candidates.

Arvind Kumar Shakya (2020) The body's primary site for nutrition processing and energy production is the liver, a crucial organ. Additionally, it is imperative for the kidney's role in the metabolism and removal of toxic chemicals or exogenous medications. Various liver illnesses like jaundice, necrosis, hepatitis, fibrosis, & cirrhosis may be caused by hepatotoxicity, which can be brought on by a number of environmental contaminants, pathogenic microorganisms, viruses, medicines, & chemical agents. The Indian traditional medical system known as ayurveda has been used to treat a variety of human ailments both historically and currently. A large supply of therapeutic chemicals utilised in the creation of successful medications for a variety of human diseases comes from medicinal plants, including those used to treat liver disorders. As a effect, the pharmaceutical industry is increasingly using medicinal plants to create safe & effective medications for the treatment of newly emerging human ailments. The goal of the current review is to gather information on medicinal plants that have been shown to be hepatoprotective against drug-induced liver damage.

Yayuan Peng et al. (2019) The liver is where drugs are metabolised most efficiently. Thus, DILI is unavoidable and has appeared as one of the major factors causal to drug development failure & product recalls. The interpretation of the processes of DILI by bioassays is time-consuming, labor-intensive, & expensive due to the absence of valid preclinical & in

www.ignited.in

vivo toxicological test settings. In this research, we investigated the molecular mechanisms of DILI using a computational system toxicology method. A total of 1478 DILI compounds, together with 1067 identified targets for 896 DILI compounds, were gathered. Then, using our bSDTNBI (balanced substructure-drug-target network-based inference) technique, 173 additional possible targets for these compounds were predicted. 26 of the 145 major genes associated with hepatotoxicity and expressed more highly in the liver were predicted by our technique, including the genes CYP2E1, GSTA1, EPHX1, ADH1B, ADH1C, ALDH2, F7, & IL2. Furthermore, the DILI-Score scoring function was put forth to evaluate the degree of hepatotoxicity of a particular substance. Last but not least, using case studies, we explore the mechanism basic DILI from the viewpoint of off-targets and identified the crucial genes responsible for the liver damage brought on by tyrosine kinase inhibitors and TAK-875. This research will help to clarify the mechanisms underlying DILI and offer suggestions for lowering risk.

Benjamin L. Woolbright et al. (2018) The significance of inflammation in acetaminophen-induced liver injury is highlighted in this article's brief summary of the processes of inflammatory liver injury and how they relate to drug hepatotoxicity. In the past ten years, considerable progress has been made in our knowledge of how damage-associated chemical patterns released by necrotic cell death are recognised by toll-like receptors or other receptors on macrophages to trigger sterile inflammation. These processes cause the synthesis of cytokines & chemokines either directly or with the aid of inflammasome activation, which activates and draws leukocytes into the necrotic zones, including neutrophils and monocyte-derived macrophages. Although the primary goals of this sterile inflammatory response are to clear away necrotic cell debris & set the stage for regeneration, there are some circumstances where these innate immune cells can exacerbate the initial injury. Innate immunity's processes and contentious results are thoroughly examined. Contrarily, drug metabolism & creation of a reactive metabolite that attaches to proteins without causing significant cell death can trigger an adaptive immune response, which ultimately also causes serious liver damage. Protein adducts, which act as haptens to trigger an adaptive immune response, seem to be the triggering event, nevertheless. In general, less is known about these mechanisms. Our knowledge of the mechanisms governing the interaction between cell death or innate or adaptive immune responses has undergone a revolution in the last ten years. This study offers a review of these systems.

Udhaya LavinyaBaskaran et al. (2017) The most typical side effect of antituberculosis medication is called DILI (ATDs). In these patients, the development of hepatotoxicity is accompanied by a number of risk factors. The sole option given to clinicians is drug withdrawal, despite the fact that research have been conducted to determine the effectiveness of several natural & synthetic medicines in reducing this impact. This review will provide a detailed understanding of ATD-induced hepatotoxicity, as well as its underlying processes & potential alternative treatments.

Bruno Vincenzi (2016) All anticancer medications have the risk of sporadic liver damage. Hepatoprotective drugs are therefore very crucial to maintaining liver health. Acute hepatitis in adults with hepatic injury accounts for 10% of cases; drug-related harm is still overestimated due to relative clinical underestimate and challenging differential diagnosis. Chemotherapeutic chemicals are not uniformly hepatotoxic; instead, they can cause liver toxicity through a variety of mechanisms, leading to a variety of types of liver damage. Anticancer-induced hepatotoxicity frequently exhibits idiosyncrasies & impacted by a variety of variables. The use of this essay is to accomplish a appraisal of the literature on liver damage brought on by anticancer medications. We discussed the mechanisms of the main anticancer drugs' hepatotoxicity & corresponding dose reductions. We also looked at studies on hepatoprotectors and the best way to use them. In a few small investigations, tiopronin, magnesium isoglycyrrhizinate, & S-Adenosylmethionine (AdoMet) showed a potential hepatoprotective action. Actually, the literature only includes small-scale experiences. Given the fact that hepatoprotective drugs seem to be beneficial in the oncologic environment, a major obstacle to the use of hepatoprotectors in cancer patients is the absence of well-designed prospective Phase III randomised controlled studies. Studies of this nature are necessary to support their use and to provide additional recommendations for the clinical setting.

Aashish Pandit et al. (2012) The primary organ for preserving the body's interior environment is the liver. Today, there is no way to make up for lost liver function. It primarily affects nutrient flow and regulates the metabolism of carbohydrates, proteins, and lipids. Drug abuse is a significant factor in liver damage. There have been over 900 substances—drugs, poisons, and herbs—reported to harm the liver. About 75% of idiosyncratic drug responses culminate in a liver transplant or death. Liver granulomas, acute fatty infiltration, cholestatic jaundice, active chronic hepatitis, liver cirrhosis, liver tumours, and so on. are only a few examples of acute liver damage that is dosage dependant. are a few examples of drug-induced liver illnesses. Acute liver failure affects about 2000 Americans each year, and pharmaceuticals are to blame for more than half of those cases (37 percent are due to acetaminophen, 13 percent are idiosyncratic reactions due to other medications). Drugs are to blame for 2-5% of individuals with jaundice who are hospitalised and for 10% of all occurrences of acute hepatitis. Approximately 4 million deaths per year are caused by chronic liver disease & cirrhosis in 17

different nations, accounting for about 2 percent of the average. This analysis focus on several medicines that create hepatotoxicity, together with their mechanism of liver damage or clinical scenario, taking into account the significance of drug-induced hepatotoxicity as a considerable cause of liver damage.

CONCLUSION

DILI is a very uncommon but possibly fatal medication side effect. The liver, a crucial organ of the body, performs vital tasks that help to maintain internal homeostasis. The liver is dependable for the toxicity from numerous intrinsic & extrinsic factors and plays a significant role in processing & eliminating toxins. It is crucial to understand the numerous mechanisms underlying drug-induced hepatotoxicity. Oxidative stress and low glutathione levels also play important roles in the pathophysiology of liver disease. As a result, an hour is required to perform a review in the field of hepatoprotection.

REFERENCES

1. Aida Ortega-Alonso, Camilla Stephens, M. Isabel Lucena, and Raúl J. Andrade. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. *Int J Mol Sci* 2016:714; 1-22.

2. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. *Clin Liver Dis* 2007;11:563-75, vi-vii.

3. Baskaran, U. L., & Sabina, E. P. (2017). Clinical and experimental research in antituberculosis drug-induced hepatotoxicity: a review. *Journal of Integrative Medicine*, *15*(1), 27-36.

4. Chen, J., Huang, D., She, M., Wang, Z., Chen, X., Liu, P., ... & Li, J. (2021). Recent progress in fluorescent sensors for drug-induced liver injury assessment. *ACS sensors*, *6*(3), 628-640.

5. Chitturi S, Farrell GC. Herbal hepatotoxicity: An expanding but poorly defined problem. *J Gastroenterol Hepatol* 2000:15:1093-9.

6. Chitturi S, George. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. *J Semin Liver Dis* 2002;22:169-83.

7. Das A., Biswas P., Chakrabarty P. (2011); Hepatotoxicity and Hepatoprotective Herbs: Herbal Remidies; International Journal of Research in Ayurveda and Pharmacy 2(4); 1073-1078.

8. Dass Ervilla & Patel. A prospective study of liver cirrhosis: An overview, prevalence, clinical manifestation & investigations in patients admitted to the medicine ward in a rural teaching hospital. Int J Sci Res 2018;7:614-6.

9. Ervilla E. Dass, Shah K. K. Paracetamol and conventional antimalarial drugs induced hepatotoxicity and its protection by methionine in rats. Indian Journal of Experimental Biology 2000; 38: 1138-1142.

10. Fernando Bessone. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? *World J Gastroenterol* 2010; 16: 5651–5661.

11. Flatland B. (2003); Botanicals, Vitamins, and Minerals and the Liver: Therapeutic Applications and Potential Toxicities; Compendium on Continuing Education for the Practising Veterinarian Practitioners; 25(7); 514-524.

12. Harshad Devarbhavi. An Update on Drug-induced Liver Injury. *J Clin Exp Hepatol* 2012;2:247–59.

13. Khouryx T, Rmeilehx AA, Yosha L, Ariel A. Benson, Saleh Daher and Meir Mizrahix. Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. *J Clin Transl Hepatol* 2015;3:99–108.

14. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. *Br J Clin Pharmacol* 2004;57:121-6.

15. Sarah J. Mitchell and Sarah N. Hilmer. Drug-induced liver injury in older adults. Ther Adv Drug Saf 2010; 1: 65-77.

16. Sartor L.L. and Trepanier L.A. (2003); Rational Pharmacologic Therapy of Hepatobiliary; Compendium on Continuing Education for the Practising Veterinarian; 25(6); 432-445.

17. Twedt D.C. (2004); The Use of Nutraceutical in Liver Disease; Proceedings of the 28th Annual Royal Canin/OSU Symposium; Columbus; Oct 16-17; 63-66.

18. Adikwu E. and Deo O. (2013); Hepatoprotective Effect of Vitamin C (Ascorbic Acid); Journal of Pharmacology & Pharmacy; 4(1); 84-92.

19. Yapar K., Kart A., Karapehlivan M., Atakisi O., Tunca R., Erginsoy S., Citil M. (2007); Hepatoprotective Effect of L-Carnitine

www.ignited.in

against Acute Acetaminophen Toxicity in Mice; Experimental and Toxicologic Pathology; 59(2); 121-128.

20. Maheswari E., Saraswathy G.R., Thakur Santhranii T. (2014); Hepatoprotective and Antioxidant Activity of N-acetyl Cysteine in Carbamazepine-Administered Rats; Indian Journal of Pharmacology; 46(2); 211-215.

21. Food & Drug Administration. CDER-PhRMA-AASLD Conference 200: clinical white paper on drug-induced hepatotoxicity, November 2000: FDA Working Group. Assessed online on 17-01-2017.

22. Mirahmad, M., Sabourian, R., Mahdavi, M., Larijani, B., & Safavi, M. (2022). In vitro cell-based models of drug-induced hepatotoxicity screening: progress and limitation. *Drug Metabolism Reviews*, *54*(2), 161-193.

23. Norman, B. H. (2020). Drug induced liver injury (dili). Mechanisms and medicinal chemistry avoidance/mitigation strategies. *Journal of medicinal chemistry*, *63*(20), 11397-11419.

24. Pandit, A., Sachdeva, T., & Bafna, P. (2012). Drug-induced hepatotoxicity: a review. *Journal of Applied Pharmaceutical Science*, (Issue), 233-243.

25. Parthasarathy, M., & Evan Prince, S. (2021). The potential effect of phytochemicals and herbal plant remedies for treating drug-induced hepatotoxicity: a review. *Molecular Biology Reports*, *48*(5), 4767-4788.

26. Peng, Y., Wu, Z., Yang, H., Cai, Y., Liu, G., Li, W., & Tang, Y. (2019). Insights into mechanisms and severity of drug-induced liver injury via computational systems toxicology approach. *Toxicology Letters*, *312*, 22-33.

27. Shakya, A. K. (2020). Drug-induced hepatotoxicity and hepatoprotective medicinal plants: a review. *Indian J Pharm Educ Res*, *54*(2), 234-50.

28. Singh A, Bhat TK, Sharma OP. Clinical Biochemistry of Hepatotoxicity. *J Clinic Toxicol* 2011;S4:001. doi:10.4172/2161-0495.S4-001.

29. Singh D, Cho WC and Upadhyay G. Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview. *Front Physiol* 2016;6:363. doi: 10.3389/fphys.2015.00363.

30. Su, H., Wang, N., Zhang, J., Lu, X., Qin, S., Wang, J., ... & Wang, J. (2022). An activatable fluorescent probe for monitoring the up-regulation of peroxynitrite in drug-induced hepatotoxicity model. *Dyes and Pigments*, *203*, 110341.

31. Sukumaran, D., Usharani, P., Paramjyothi, G. K., Subbalaxmi, M. V. S., Sireesha, K., & Ali, M. A. (2022). A study to evaluate the hepatoprotective effect of N-acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. *Indian Journal of Tuberculosis*.

32. Vargas-Mendoza N., Madrigal-Santillan E, Morales-González A, Esquivel-Soto H, Esquivel-Chirino C, González-Rubio G.M., Gayosso-de-Lucio J.A. (2014); Hepatoprotective effect of silymarin; World Journal of Hepatology; 6(3); 144-149.

33. Vincenzi, B., Armento, G., Spalato Ceruso, M., Catania, G., Leakos, M., Santini, D., ... & Tonini, G. (2016). Drug-induced hepatotoxicity in cancer patients-implication for treatment. *Expert opinion on drug safety*, *15*(9), 1219-1238.

34. William M. Lee, M.D. Drug-Induced Hepatotoxicity. *N Engl J Med* 2003;349:474-85.

35. Woolbright, B. L., & Jaeschke, H. (2018). Mechanisms of inflammatory liver injury and drug-induced hepatotoxicity. *Current pharmacology reports*, *4*(5), 346-357.

36. Xianni, W. E. I., Huiyi, X. U., & Genying, X. I. E. (2022). Influencing factors and treatment of drug-induced liver injury. *Chinese Journal of Pharmacovigilance*, *19*(6), 665.

37. Zimmerman, H. J. Drug-induced liver disease: An overview. *Seminars Liver Dis* 1981;1: 93-103.

Corresponding Author

Santosh Kumar Chaturvedi*

Research Scholar, Lords University, Alwar, Rajasthan